Abstract ADAMTS-2 is a metalloproteinase that plays a key role in the processing of fibrillar procollagen precursors into mature collagen molecules by excising the aminopropeptide. We demonstrate that recombinant ADAMTS-2 is also able to reduce proliferation of endothelial cells, and to induce their retraction and detachment from the substrate resulting in apoptosis. Dephosphorylation of Erk1/2 and MLC largely precedes the ADAMTS-2 induced morphological alterations. In 3-D culture models, ADAMTS-2 strongly reduced branching of capillary-like structures formed by endothelial cells and their long-term maintenance and inhibited vessels formation in embryoid bodies (EB). Growth and vascularization of tumors formed in nude mice by HEK 293-EBNA cells expressing ADAMTS-2 were drastically reduced. A similar anti-tumoral activity was observed when using cells expressing recombinant deleted forms of ADAMTS-2, including catalytically inactive enzyme. Nucleolin, a nuclear protein also found to be associated with the cell membrane, was identified as a potential receptor mediating the antiangiogenic properties of ADAMTS-2.
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Introduction Angiogenesis, the process by which neovasculature is formed from existing blood vessels, is essential in normal development and plays a critical role in several pathological conditions such as cancer, rheumatoid arthritis, and diabetic retinopathy [1, 2] . Vascularization of tumors is critical for their growth beyond a few mm 3 [3] and for cancer cells to escape to distant sites through hematogenous spreading and metastasis. Accordingly, it was proposed that inhibition of angiogenesis could be an efficient anti-cancer therapy that further targets genetically stable cells [3] . In this context, identification and characterization of endogenous inhibitors of blood vessel formation is of critical importance. It is anticipated that they should be less prone to induce side-effects and resistance to treatment than synthetic inhibitors.
In recent years, a number of endogenous inhibitors of angiogenesis have been identified, many of them deriving from extracellular matrix (ECM) components. Some of these inhibitors are effective either as native full-length proteins or as proteolytic fragments [2] . This is the case for thrombospondins (TSP) 1 and 2, for which the mechanisms leading to inhibition of angiogenesis have been extensively studied and characterized [4] . Short sequences present in the N-terminal domain, especially in the thrombospondin type 1 repeats (TSR1), are released by ADAMTS-1 [5] and inhibit angiogenesis by interacting with the CD36 scavenger receptor [6] [7] [8] . Another class of inhibitors are active only as fragments derived from larger matrix macromolecules such as type XVIII collagen (endostatin), type XV collagen (restin), the a1, a2, and a3 chains of type IV collagen (arresten, canstatin, and tumstatin) and perlecan (endorepellin) [1] . Signaling from these molecules most probably involves binding or interference with specific integrins [1, 9] . A third class of angiogenesis regulators comprises secreted enzymes, most of which are proangiogenic by facilitating endothelial cells migration through degradation of matrix macromolecules and promoting the release of pro-angiogenic cytokines and growth factors immobilized in the ECM. However, some of these enzymes can also, in defined circumstances, inhibit angiogenesis. Angiostatin, a potent inhibitor of angiogenesis, is a proteolytic fragment of plasminogen [10, 11] and matrix metalloproteinases can generate anti-angiogenic fragments by proteolytic processing of some ECM proteins (see above, and [12] ). As another example, two metalloproteinases of the ADAMTS family, ADAMTS-1 and -8, were also reported to strongly inhibit angiogenesis [13, 14] . The most striking characteristic of the ADAMTS enzymes is the presence, in addition to the metalloproteinase and disintegrin domains, of at least one domain highly similar to the TSR1 found in thrombospondins 1 and 2. Studies investigating the anti-angiogenic properties of ADAMTS-1 suggest that several domains are implicated, including a TSR1 domain [15] . The catalytic activity of ADAMTS-1 is also implicated in its antiangiogenic function since it alters in vitro endothelial cells adhesion and migration [15] and is essential for inhibiting angiogenesis in vivo in xenograft assays [16] . It may also act by interacting with VEGF [13] .
Among the other members of the ADAMTS family, ADAMTS-2 is one of the best characterized [17, 18] . It contains four TSR1 domains and a RGD sequence in a Cys-rich domain that could potentially bind to integrins. Its primary function is to cleave the amino propeptides of type I, II, III and V procollagens [19] [20] [21] , explaining its previous name ''aminoprocollagen peptidase''. Mutations in the ADAMTS-2 gene cause dermatosparaxis in human (dermatosparactic type of Ehlers-Danlos syndrome, also known as Ehlers-Danlos syndrome type VIIC) and other mammals [20, 22] . This inherited connective tissue disorder arises as a result of accumulation of incorrectly processed aminoprocollagen and its cardinal feature is an extreme skin fragility. Adamts2 knockout mice have been created [23] . In addition to skin fragility, male infertility was related to altered maturation of spermatogonia, suggesting that ADAMTS-2 may have functions other than procollagen processing. An alternative splicing mechanism and complex maturation processes of the secreted enzyme have been described, generating various polypeptides that are not implicated in procollagen processing [19] .
In this work, the anti-angiogenic properties of ADAM-TS-2 in vitro and in vivo are demonstrated and initial characterizations of the mechanisms involved in its biological activity are reported.
Materials and methods
Cell cultures
Human umbilical vein endothelial cells (HUVEC) were isolated as previously described [24] . Human dermal microvascular endothelial cells (HMVEC) were purchased from LONZA (LONZA, Verviers, Belgium). HUVEC and HMVEC were seeded on gelatin-coated culture dishes and grown in endothelial basal medium (EBM) supplemented with SingleQuot Ò Kit (LONZA). Human microvascular endothelial cells (HMEC) [25] , human primary skin fibroblasts (HSF) [26] , and human smooth muscle cells (HSMC) [27] were grown in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Grand Island, NY) supplemented with 10% FBS (LONZA). Heparinase III and chondroitinase were purchased from Sigma (SigmaAldrich, St. Louis, MO, USA).
Production and purification of wild recombinant ADAMTS-2 and controls Recombinant bovine ADAMTS-2 was produced in HEK 293-EBNA cells as previously described [19] . Although recombinant ADAMTS-2 was highly purified [19] , co-purification of any product secreted by HEK 293-EBNA cells that could potentially hamper the analysis of experimental data could not be totally excluded. In order to take into account this possibility, control samples were produced from HEK 293-EBNA cells transfected with the empty vector using the same purification procedures as described for recombinant ADAMTS-2. The electrophoretic patterns of purified control medium and of purified ADAMTS-2 was determined on a SDS-PAGE stained with SYPRO Ò Ruby Protein Gel Stain (BioRad, Hercules, CA) as described by the manufacturer. For any experimental condition, the effect of ADAMTS-2 was always compared to the effect observed with a similar volume of the purified control medium.
Cell proliferation assay
Cell proliferation assays were performed by two different methods. In the first one, cells were seeded (HMEC: 2.5 9 10 4 cells/cm 2 ; HUVEC, HMVEC, HSF: 1 9 10 4 cells/cm 2 ) in 24-multiwell plates (Cellstar, Greiner Bioone Frickenhausen, Germany) coated with gelatin in EBM supplemented with 0.5% FBS. After 3 h, the medium was discarded and cells were incubated in EBM containing 0.5% FBS and ADAMTS-2 or the control sample. After 24 h, the culture medium was replaced by the same medium containing 0.4 lM [ 3 H]-thymidine (6.7 Ci/mmol; PerkinElmer Life Sciences, Boston, MA, USA) and 0.6 lM cold thymidine (Sigma-Aldrich). After 20 h, cells were washed twice with DMEM and sonicated in 500 ll PBS. Incorporation of thymidine was determined by measuring the TCA (cold, 5% final) insoluble radioactivity collected by filtration on glass microfiber filters (GF/A, Whatmann, Maidstone, United Kingdom).
For the second method, HEK 293-EBNA cells were seeded (1.6 9 10 4 cells/cm 2 ) in 6-multiwell plates (Cellstar) in DMEM supplemented with 10% FBS. At days 0, 1, 2, 3, 4 and 5, the DNA was measured by a fluorimetric technique using bis-benzimide [28] .
Cell morphology and immunocytochemical staining
In a first set of experiments, cells were seeded on gelatincoated 24-multiwell plates in EBM supplemented with 0.5% FBS. In a second set of experiments, cells were seeded in non-supplemented EBM on gelatin-coated or fibronectin-coated (0.25 lg/cm 2 ) 4-wells LabTekÓ chambered coverglasses (Nalge Nunc International, IL, USA) for immunocytochemical staining or on gelatin-coated or fibronectin-coated 24-multiwell plates for observation by phase contrast microscopy. For all experiments, the medium was discarded after 3 h of attachment and spreading, and replaced by fresh medium containing, when indicated, 5 lg/ml of ADAMTS-2 or control sample. After 16 h, cells were fixed with 3% formaldehyde in PBS for 30 min and permeabilized for 3 min in PBS containing 0.1% Triton Ò X-100 (Merck, Darmstadt, Germany). Vinculin staining was performed using a monoclonal antibody against vinculin (dilution 1:1,000 for 1 h; V9131; Sigma-Aldrich) followed by Alexa Fluor 546 rabbit anti-mouse IgG (2 lg/ml final concentration, for 1 h; Molecular Probes, Eugene, OR, USA), F-actin was stained with 100 ng/ml FITC-Phalloidin (Sigma-Aldrich) in PBS for 20 min. Nuclei were stained with 0.2 lg/ml bis-benzimide (Calbiochem, La Jolla, CA, USA) in PBS. After mounting using Aqua Poly/Mount (Polysciences, INC, Warrington, PA, USA), cells were observed with Zeiss Axiovert 25 microscope equipped with an Axiocam Zeiss camera and the KS 400 Kontron image analysis software.
Time-lapse video imaging HUVEC and HSF were seeded (3.3 9 10 4 cells/cm 2 ) in Glass Bottom Culture Dishes No. 1.5 coated with collagen (MatTek Co, Ashland, MA) in EBM supplemented with 0.5% FBS. After 5 h, the medium was replaced by fresh medium containing 5 lg/ml of ADAMTS-2 or control sample. Time-lapse videomicroscopy was performed using a Leica TS-2 confocal microscope (Leica, Wetzlar, Germany). Images were recorded every 5 min for 20 h. All time-lapse imaging was performed under 5% CO 2 and 37°C in a controlled stage incubator.
Western-blot analysis HUVEC were seeded (3.3 9 10 4 cells/cm 2 ) on gelatincoated 24-multiwell plates in serum-free EBM. After 3 h, ADAMTS-2 was added in the medium to obtain a final concentration of 5 lg/ml. The same volume of the control sample was used in parallel cultures. After increasing the time of incubation, the cells were lyzed in Laemmli denaturation buffer. Proteins were separated by SDS-PAGE and transferred onto a PVDF membrane (NEN Life Science Products, Boston, MA, USA). After blocking with non-fat milk, membranes were incubated with primary antibody, washed, and then incubated with horseradish peroxidase-conjugated secondary antibodies (Dako, Carpinteria, CA, USA) at room temperature for 1 h. The blots were revealed by using an enhanced chemiluminescence assay (ECL, Amersham Biosciences Ltd, England) and X-ray film exposure. The antibody reagents used were: anti-phospho-p38 MAP Kinase (Biosource P0601, Camarillo, CA, USA); anti-phospho-p42/ 44 4 cells/cm 2 ) on gelatincoated 12-multiwell plates (Cellstar) in serum-free EBM or in EBM supplemented with 0.5% FBS. After 3 h, medium was replaced by EBM containing 5 lg/ml ADAMTS-2 and supplemented or not with 0.5% FBS. After 30 min, 120 min, 240 min, or 18 h of incubation, medium was collected and cells were trypsinized, pooled with the medium, and centrifuged to collect any floating cells. Cells were then suspended in Annexin binding buffer (Annexin V-FITC Apoptosis Detection kit, Sigma) at the concentration of 1 9 10 5 cells/ml and incubated for 10 min with Annexin V-FITC (270 ng/ml) and propidium iodide (1.1 lg/ml). Cell analysis was performed using FACS (BD FACS Canto, BD Biosciences) and statistical significance was determined using one-way ANOVA test.
ADAMTS-2 immunostaining
HMEC were seeded in DMEM medium supplemented by 10% FBS. After 16 h, the medium was discarded and cells were incubated for 6 h at 8°C in serum-free medium containing, when indicated, 0.5 or 2 lg/ml of ADAMTS-2 or control sample, supplemented or not with heparin (10 lg/ml; Sigma-Aldrich). For other experiments, cells were first pretreated with 6 mU/ml heparinase III (4 h at 37°C) or 0.1 U/ml chondroitinase (4 h at 37°C), or with 20 mM sodium chlorate with or without 10 mM sodium sulfate (16 h at 37°C) before incubation with ADAMTS-2 or control sample. For all these experiments, cells after incubation with ADAMTS-2 were washed with DMEM and fixed with 3% paraformaldehyde at room temperature for 30 min. The washed cell layer was incubated sequentially in PBS containing 3% bovine serum albumin for 30 min, mouse monoclonal antibodies against ADAMTS-2 for 1 h (mAb23; [19] ), Alexa Fluor 546 rabbit anti-mouse IgG for 1 h (Molecular Probes, A-11060), and, when indicated, rabbit polyclonal anti-human nucleolin (H250, Santa Cruz Biotechnology) and Alexa Fluor 488 goat antirabbit IgG for 1 h (Molecular Probes, A-11034). Nuclei staining was performed using DAPI at 1 lg/ml for 20 min (Roche, 236276). After mounting in Aqua Poly/Mount (Polysciences) cells were observed with a Zeiss Axiovert 25 inverted microscope.
Isolation and identification of ADAMTS-2-binding proteins
Antibody against ADAMTS-2 (mab23, [19] ) was immobilized on a Affi-gel Ò HZ resin (Bio-Rad) as described by the manufacturer. Purified recombinant ADAMTS-2 was then incubated with resin in order to allow immobilization of ADAMTS-2 by binding with antibody against ADAM-TS-2. Resin without ADAMTS-2 was used as control.
Resins were poured in a column and equilibrated in 50 mM Tris HCl, pH 7.5, 2 mM CaCl 2 , 0.1 M NaCl. HMEC were scraped from the dish and incubated 30 min on ice in extraction buffer (0.2% Triton X-100, pH 7.0, 100 mM N-ethylmaleimide, 0.2 mM phenylmethanesulfonyl fluoride, 5 mM benzamide). Cells were then centrifuged 25 min at 20,000 9 g. Supernatant was collected, diluted in one volume of equilibration buffer containing NaCl to obtain 0.1% Triton X-100 and 0.1 M NaCl final concentration and loaded on column with immobilized ADAMTS-2 or on control resin. After extensive washing in the equilibration buffer, elution was performed (50 mM Tris HCl, pH 7.5, 2 mM CaCl 2 , 0.5 M NaCl). Eluted fractions were dialyzed against 200 mM ammonium acetate and 0.01% sodium dodecyl sulfate, lyophilized, and resuspended in Laemmli buffer. Proteins were then separated by SDS-PAGE and stained by Coomassie Blue. The differential pattern between the control and ADAMTS-2 affinity chromatography allowed to identify potential proteins of interest. Their identification was performed after extraction from the polyacrylamide gel by micro high-performance liquid chromatography-electrospray ionization-trap (lHPLC-ESITrap; Esquire-Bruker Daltonics, Billerica, MA).
Capillary-like structures formation assay
The capillary-like structures assay was performed as previously described [29] . When indicated, 2 or 5 lg/ml ADAMTS-2 or control sample was added to the collagen solution and to the medium. Changes in cell morphology and formation of capillary-like structures were evaluated by phase-contrast microscopy. The mean length of the structures and the number of branching per mm 2 were determined.
Embryoid bodies
Undifferentiated embryonic stem CGR8 (ES) cells were aggregated by culture on bacteriological dishes during 4 days in a 20-ll hanging drop of DMEM supplemented with 10% FBS, 0.1 mM non-essential amino acids, 0.1 mM b-mercaptoethanol, and 10 ng/ml of VEGF to induce cell clustering and differentiation into endothelial cells [30] . The aggregates were seeded on gelatin-coated glass coverslips in the same medium supplemented with recombinant ADAMTS-2 or control sample. Media were renewed every 48 h for 8 days. For immunohistochemistry, the embryoid bodies were fixed in methanol and incubated with rat anti-mouse CD31 antibodies (Pharmingen, San Diego, CA), biotin-conjugated anti-rat IgG, and streptavidin/FITC. Nuclei were stained with 0.2 lg/ml bisbenzimide (Calbiochem) in PBS. The surface of the embryoid body and the total vessel length by representative microscope field was determined by manual measurement on enlarged pictures.
Growth of HEK 293-EBNA tumors in nude mice
HEK 293-EBNA cells transfected with ADAMTS-2 cDNA (wild-type, mutated, or truncated) or empty vector [19] were resuspended at 4°C in growth factor-depleted Matrigel (BD Biosciences) solubilized in serum-free DMEM to a final concentration of 2 9 10 7 cells/ml. Cell suspension (100 ll) was injected subcutaneously into the flanks of mice, each mouse being injected with HEK 293-EBNA cells transfected with ADAMTS-2 on the left side and with HEK 293-EBNA cells transfected with empty vector on the right side. Tumor size was monitored every 3-4 days by measuring two perpendicular diameters and the height using a caliper. Mice were killed according to the animal ethical policy of the University of Liège when the apparent size of the tumor exceeded 1,500-2,500 mm 3 . Tumors were weighed and then fixed in buffered 3% paraformaldehyde solution for routine histology or embedded in optimal cutting temperature compound (Tissue TeK, Miles Laboratories, Naperville, Ill) and frozen for cryostat sectioning. Cryostat sections (5 lm thick) were fixed first in acetone at -20°C and then in methanol at 4°C before incubation with rat monoclonal antibody against mouse platelet endothelial cell adhesion molecule (PECAM) (Pharmingen). Slides were then incubated with rabbit antirat antibody coupled with biotin (E468, Dako) followed by incubation with streptavidin/HRP complex (PO397, Dako). Slides were finally counterstained with hematoxylin and mounted with Eukitt medium for microscope observation.
Results
Recombinant ADAMTS-2 was produced and purified from medium conditioned by HEK 293-EBNA cells transfected with an ADAMTS-2 expression vector. A control sample was produced using HEK 293-EBNA cells transfected with an empty vector and submitted to a purification process identical to that used for recombinant ADAMTS-2. Both preparations were used in parallel in the following experiments.
Effect of ADAMTS-2 on cell proliferation
Recombinant ADAMTS-2 added at increasing concentrations (0.8-5 lg/ml, corresponding to 7-44 nM) significantly reduced the 3 H-thymidine uptake by HUVEC after 2 days of contact as compared to the cells treated with the control sample taken as 100% (Fig. 1a, black bars) . A similar inhibition of the proliferation was also observed when using HMVEC in the same conditions (Fig. 1a, dark grey bars) . No significant effect was found for fibroblasts (Fig. 1a, clear grey  bars) . The anti-angiogenic effect of ADAMTS-2 was as effective when endothelial cell proliferation was stimulated by VEGF and/or FGF-2 (not shown).
ADAMTS-2 alters endothelial cells morphology and cytoskeleton
After 3 h of seeding on gelatin coat, the three types of endothelial cells (HUVEC, HVMEC, and HMEC) had already well spread (not shown) and their morphology did not change during an additional 16 h incubation in control medium (Fig. 1Ba, b, c) . In the presence of ADAMTS-2, subtle changes in endothelial cell morphology were already observed after 15-20 min and accentuated with time ( Fig. 1Bd, e, f) . Many cells appeared more refringent, retracted and rounded, and clustered into aggregates with many cell protruding processes resembling filipodia and podosomes. Similar results were obtained for bovine aortic endothelial cells (BAEC) (not shown) or for HUVEC and HMEC seeded on gelatin or fibronectin (Fig. S1 ) or on collagen (not shown). In contrast, ADAMTS-2 did not alter the morphology of human skin fibroblasts (HSF) or smooth-muscle cells (HSMC) (Fig. 1B , compare g, h to i, j).
In order to better visualize the dynamics of the process, time-lapse video microscopy was performed (available as supplemental material). In control conditions, cells remained well-spread, actively formed membrane ruffles and did not migrate at long distance. In the presence of ADAMTS-2, endothelial cells progressively lost their adherence to the substrate, migrated farther and faster, established cell-cell contacts, assembled into clusters and finally died after 1 day. The same experiment performed with fibroblasts did not show any significant morphological or dynamic changes (not shown).
The organization of the cytoskeleton of HUVEC cultured on fibronectin was visualized by staining fibrillar actin (Fig. 2a) and focal adhesions (Fig. 2b) . In control conditions, HUVEC displayed actin stress fibers anchored into focal adhesions as seen in the merged pictures (Fig. 2S) . Treatment by ADAMTS-2 for 16 h (Fig. 2c, d ) resulted in a disruption of the network of actin stress fibers and dissolution of many focal adhesions, leaving streaks of cortical actin along the protruding processes. Similar results were obtained with HUVEC cultured on gelatin in the presence of ADAMTS-2 (not shown).
ADAMTS-2 induces apoptosis in HUVEC
HUVEC were stained with annexin V-FITC and propidium iodide (PI) and analyzed by FACS in order to evaluate the induction of apoptosis by ADAMTS-2 in the various culture conditions. Due to their limited lifespan in vitro and their high sensitivity towards culture conditions, especially in reduced serum concentration, some apoptotic HUVEC were detected in control conditions (Fig. 3a) . Staurosporine, used as positive control, strongly increased apoptosis already after 4 h (Fig. 3b, c, grey bars) . In the presence of ADAMTS-2, apoptosis tended to raise already after 4 h and was strongly increased after 20 h as compared to the respective control conditions (Fig. 3b, c, black bars) , confirming the time lapse videomicroscopy data (supplemental material). (Fig. 4 , compare e to a, c). This is in agreement with morphology data showing that addition of ADAMTS-2 does not affect cell migration and cell-cell interactions. However, while the capillary-like structures remained stable for at least 4-5 days in the cultures either containing medium supplemented with FBS alone (Fig. 4Ab, b 0 ) or further supplemented with the control preparation (Fig. 4Ad, d 0 ), the organization of the tube-like structures in the cultures supplemented with ADAMTS-2 was strongly altered after 36 h (Fig. 4Af, f 0 ), with short segments of disassembled vessels and many isolated cells being observed. The quantification of the mean length and number of branchings of the capillary-like structures in the various culture conditions (Fig. 4b, c) further confirmed visual observation.
ADAMTS-2 inhibits vessels formation in embryoid bodies
The properties of ADAMTS-2 were further evaluated in vitro on the differentiation of ES cells into vascular structures in EB induced by VEGF. The vessels were visualized by detection of CD31, in whole-mount immunofluorescence microscopy, as a peripheral ring of elongated and branched tubular structures (Fig. 5A) . As compared to controls, addition of ADAMTS-2 resulted in a significant reduction of the vessel density (Fig. 5b) without modifying the overall growth of EB as illustrated by DAPI staining of the nuclei (Fig. 5Aa, c) . Furthermore, beating heart in EB was not altered by ADAMTS-2 (not shown) as additional evidence that the differentiation and function of other cell types were not impaired.
ADAMTS-2 binds to endothelial cells surface
Live endothelial cells in monolayer cultures were incubated with ADAMTS-2 or the control preparation at 8°C in order to prevent internalization. After fixation and labeling of the non-permeabilized cells with an anti-ADAMTS-2 monoclonal antibody, an intense and punctated staining of endothelial cell surface was observed in cultures supplemented with ADAMTS-2 (Fig. 6, compare a and b) . Fibroblasts were also positive (Fig. 6c) . In the presence of heparin, the labeling was strongly reduced but not completely abolished (Fig. 6d) . Similar effects were observed when cells were pre-treated with sodium chlorate in order to prevent sulfation process (Fig. 6e) . This inhibition was completely reversed by adding sodium sulfate together with chlorate to restore sulfation (Fig. 6f) . These results suggested the involvement of binding motifs containing heparan sulfate. Similarly, a heparinase III pretreatment strongly reduced, but did not completely abolish, ADAMTS-2 binding at the cell surface (Fig. 6g) , while digestion with chondroitinase had no effect (Fig. 6h) . In another set of experiments, cells initially preincubated with ADAMTS-2 at 8°C were brought to 37°C and immunostained at increasing time after re-warming. In these conditions, an active internalization process was visualized already after 15 min and was almost complete after 2 h (not shown).
Although the participation of heparan sulphate proteoglycans (HSPG) in ADAMTS-2 immobilization at the cell surface was firmly established, heparinase III pretreatment did not significantly modify the effect of ADAMTS-2 on endothelial cell morphology and proliferation (not shown), suggesting the existence of a signaling cell surface receptor. For its identification, extracts of endothelial cell membranes were submitted to column chromatography on either immobilized ADAMTS-2 as a bait or non-coupled resin as control. Besides a few unspecific proteins eluting from both columns, nucleolin was identified by peptide mass fingerprinting in two fractions specifically eluted from the ADAMTS-2 coupled resin. These data were further confirmed by Western blotting, which identified four different processed forms of nucleolin (Fig. S3) .
Co-localization studies were performed in order to evaluate the interaction between ADAMTS-2 and nucleolin in a cellular context. Non-permeabilized endothelial cells were successively pretreated with heparinase III, incubated at 8°C with ADAMTS-2 and fixed before double immunostaining of ADAMTS-2 and nucleolin (Fig. 7) . The pattern of surface nucleolin was punctated and spread over the entire cell surface. The nuclei remained negative, confirming the absence of cell permeabilization. Staining of ADAMTS-2 also revealed a punctated pattern. These positive spots were less numerous than spots positive for nucleolin but always colocalized with nucleolin positive structures as illustrated by the yellow to orange colors on the merge pictures. Most of these double-positive spots were localized at the cell edge.
ADAMTS-2 intracellular signaling
The phosphorylation status of various signaling proteins was assessed after addition of ADAMTS-2 to serumstarved spread HUVEC. A slight repression of FAK phosphorylation was induced by addition of ADAMTS-2, as compared to control (Fig. 8a) . A progressive reduction of the total amount of FAK with time was also observed in some experiments but was not further investigated since it was not regulated by the presence of ADAMTS-2. Myosin light chain, an operational protein of the actin stress-fibers, was investigated. A decreased level of phosphorylation was already apparent after 10 min of incubation with ADAM-TS-2 and persisted for at least 2 h (Fig. 8b) . By using Y27632, a Rho kinase (ROCK) inhibitor, the level of phosphorylated MLC was also strongly reduced (not shown). However, this reduction did not result in alteration of cell morphology, and did not prevent or increase the effect of ADAMTS-2. The level of phosphorylated Erk1/2 Fig. 6 Binding of ADAMTS-2 at the cell surface. HMEC (a, b, d-h) and fibroblasts (c) were incubated for 6 h at 8°C in serum-free medium supplemented with control preparation (a) or ADAMTS-2 at 2 lg/ml (b-h) in the absence (a-c, e-h) or presence of 10 lg/ml heparin (d) and then immunostained for the presence of ADAMTS-2 immobilized at the cell surface. For a second set of experiments, HMEC were first pretreated for 16 h with 20 mM sodium chlorate alone (e) or with sodium chlorate in the presence of 10 mM sodium sulfate (f) or for 4 h with 6 mU/ml heparinase III (g) or 0.1 U/ml chondroitinase (h). After pre-treatment, medium was changed and cells were cultured for 6 h at 8°C in the presence of ADAMTS-2 before staining as described above. Bar 50 lm decreased with time in control conditions while a much faster reduction of phosphorylation was induced by ADAMTS-2 in HUVEC (Fig. 8c) whereas it was not modified, or even slightly increased, in fibroblasts (Fig. 8d) . Phosphorylation of two other signaling proteins, PAK and p38, was not modified by ADAMTS-2 (not shown).
Targeted deletion of ADAMTS-2 in mice results in an increased angiogenic response to ocular LASER injury
Wild-type (WT) and ADAMTS-2 deficient (ADAMTS-2 -/-) mice were used in a model of choroidal neovascularization following LASER burn injury. Fourteen days after LASER impact, the delay for maximal neovascularization [31] , the mice were perfused with dextranfluorescein and the vascular density was evaluated using confocal microscopy and digital image capture. Neovascularization was observed only at the sites initially injured by the LASER and was significantly and reproducibly higher in ADAMTS-2 -/-as compared to WT mice (Fig. S4) . Evaluation, by quantitative RT-PCR, of the level of various mRNA coding for proteins involved in healing and angiogenesis as listed in Table S1 (supplemental material) was also performed. No difference was observed between WT and ADAMTS-2 -/-for any mRNA and at any time point after LASER burn (not shown). HUVEC (a, b, c) or fibroblasts (d) were seeded in serumfree medium and allowed to spread for 3 h at 37°C. ADAMTS-2 (TS-2) and control preparation (CTRL) were then added for various times. Cell lysates were analyzed by Western blotting using antibodies for phosphorylated FAK (p-FAK) and total FAK (a), phosphorylated MLC (p-MLC) and total MLC (b) and phosphorylated Erk1/2 (p-Erk1/2) and total Erk1/2 (c, d). Scanning density of the bands obtained in at least three independent experiments was used to calculate the relative level of p-FAK versus total FAK (n = 6) (a 0 ), p-MLC versus total MLC (n = 3) (b 0 ) and p-Erk1/ 2 versus total Erk1/2 (n = 8) (c 0 , d 0 ) in the various cultures conditions (***p \ 0.001; **p \ 0.01) (Fig. 9a) . By contrast, tumoral development was not observed in the ADAMTS-2 expressing cells, only one out of the six ADAMTS-2 plugs starting to slightly grow at day 30. After killing, dissected tumors were weighed, clearly demonstrating a dramatic difference in the mean tumoral mass (Fig. 9b) . While control tumors appeared reddish with a well-developed peritumoral vascular network (Fig. 9c) , ADAMTS-2 expressing tumors were whiter and little vascularized. A Western-blot analysis failed to reveal significant accumulation of ADAMTS-2 at the time of the animal killing, suggesting that most of the HEK 293-EBNA cells expressing ADAMTS-2 either died or stopped to produce ADAMTS-2. This was confirmed by immunohistochemistry analysis showing that only a few cells at the periphery of tumors was still producing ADAMTS-2 (not shown). A second independent experiment (n = 4) performed in similar conditions gave identical results, further demonstrating the efficiency and the reproducibility of the inhibition (Fig. 12a) . Histological examination revealed the presence of large aggregates of HEK 293-EBNA cells in control tumors (Fig. 10a) , containing both capillaries and larger vessels (Fig. 10b) . In the small tumors formed by cells expressing ADAMTS-2, necrotic areas and collapsed vessels were noted (Fig. 10a, b) .
The catalytic activity of ADAMTS-2 is dispensable for antiangiogenic activity Three additional constructs coding for catalytically inactive ADAMTS-2 or for ADAMTS-2 lacking either the central or the C-terminal domains were created and used for stable transfection of HEK 293-EBNA cells. The proliferation rate of these cell lines in vitro was similar and close to that of the control cells or cells expressing the wild-type enzyme (Fig. 12e) . These cells were also used for the production of recombinant enzymes. Out of these three ADAMTS-2 mutants, only the catalytically inactive form could be purified using the protocol developed for the wildtype enzyme. The electrophoretic pattern of these two recombinant forms was strongly different (Fig. 11a) since the wild-type form was essentially found as a fully processed molecule from which both the prodomain and the PNP domain are cleaved while the catalytic mutant still retained the PNP domain as previously described [19] . Their relative effects were compared in various in vitro models. The catalytic mutant was able to modify both the morphology (Fig. 11b) and the proliferation rate (Fig. 11c ) of endothelial cells although less drastically than observed for the wild-type enzyme. Both types of enzymes bound also with a similar efficiency to the surface of endothelial cells (Fig. 11d) .
The cell lines expressing the wild-type and the three mutant forms of ADAMTS-2 were evaluated for their ability to generate tumors (Fig. 12a-d) . While the injection of control cells resulted in the formation of rapidly growing tumors, none of the three mutant cell lines induce significant tumoral growth. This shows that the three mutated forms of ADAMTS-2, including the catalytically inactive form, were as efficient as the wild-type enzyme for preventing tumor growth.
Discussion
Angiogenesis plays a critical role in cancer progression and metastasis [32] . Tumor growth and dissemination have been shown to be dependent on neovascularization, explaining why inhibition of tumoral angiogenesis by selectively inhibiting growth, survival, and migration of endothelial cells is still perceived today as an attractive tool for controlling cancer progression [3, 33, 34] . The potential anti-angiogenic properties of ADAMTS-2 were hypothesized on the basis of similarities between sequences and domains involved in the inhibitory activity of thrombospondin 1 and 2 and ADAMTS-1 and -8. Antiproliferative properties of recombinant ADAMTS-2 was first investigated on endothelial cell cultures in monolayer. ADAMTS-2 reproducibly inhibited the proliferation of microvascular and umbilical vein endothelial cells, with a maximal repression observed between 1 and 5 lg/ml. These concentrations (*5-40 nM) are in the same range as those reported for thrombospondin 2 [35] and ADAMTS-1 and -8 [14] . At similar concentrations, the proliferation of human fibroblasts and smooth-muscle cells was not altered, demonstrating the specificity towards endothelial cells. As opposed to ADAMTS-1 [13] , the anti-proliferative effect of ADAM-TS-2 on endothelial cells does not seem to result from interactions with a growth factor or interference with a growth factor pathway as the relative repression exerted by ADAMTS-2 was similar in the absence or presence of VEGF and/or FGF-2.
Morphological changes induced by ADAMTS-2 were evaluated using cells cultured on various extracellular matrices in the absence of any mitogenic stimulus. The alterations, observed within the first hour of contact and worsening with time, consisted of a progressive detachment and retraction of the cellular body with the persistence of thin extensions resembling filipodia. Actin cytoskeleton and focal adhesions were also rapidly and profoundly disorganized. The observed changes were similar in endothelial cells spread onto various extracellular matrix proteins, suggesting that either most of the integrins are targeted by ADAMTS-2 or that they are not involved in the process. Analysis of the entire process by videomicroscopy clearly confirmed the progressive loss of contact between endothelial cells and the matrix, further resulting in rapid random cell movements, formation of cell clusters, and ultimately cell death. The presence of numerous blebbing cells and the results of FACS analysis were both indicative of a pro-apoptotic activity of ADAMTS-2, most probably by anoikis.
The rapidity of the effect of ADAMTS-2 strongly suggested the existence of early alterations of intracellular regulatory pathways. Addition of ADAMTS-2 to endothelial cells indeed resulted in a reduced phosphorylation of MLC within 10 min, a feature that would explain the fast and pronounced disorganization of the actin cytoskeleton and rounding of the cells. The decreased phosphorylation of FAK observed at later time points in ADAMTS-2 treated cells might also result from such cytoskeleton disruption. In astrocytes, the RhoA/ROCK1/ MLC pathway regulates the process of actin reorganization, cell retraction and rounding, and anoikis [36] . In our cells, inhibition of ROCK by Y27632 strongly decreased the level of phosphorylated MLC, demonstrating the efficiency of this inhibitor, but did not mimic (neither prevent) the effect of ADAMTS-2. This indicated that this specific pathway was not essential in our model. Similarly, Rac1-, Cdc42-, and p38-mediated pathways did not seem to be involved since the phosphorylation of PAK and p38 was not modified. By contrast, binding of ADAMTS-2 to the endothelial cell surface rapidly repressed the phosphorylation of Erk1/2, an ubiquitous intracellular mediator implicated in various pathways regulating a large array of cell functions. A similar effect on Erk1/2 activity was recently observed for ADAMTS-12 using Madin-Darby Canine Kidney (MDCK) cells [37] . This inhibition was already evident after 10 min, before any visible morphological alterations, suggesting that modification of the Erk1/2 signaling is perhaps one of the causes (not consequences) of the disorganization of actin cytoskeleton. This is also in agreement with our data regarding fibroblasts. Although these cells bind a large amount of ADAMTS-2 at their surface, they are not affected in terms of morphology and survival, which correlates with a different pattern of response in terms of Erk1/2 phosphorylation.
The rapid and strong response of endothelial cells to ADAMTS-2 suggested a direct interaction between cells and the enzyme. Such interaction was evidenced after incubation of endothelial cells with recombinant ADAM-TS-2 and visualization of cell surface-bound enzyme. Interestingly, fibroblasts were also strongly labeled, although they were not affected by ADAMTS-2 in terms of survival, proliferation, and morphology. ADAMTS-2 binding to the endothelial cell surface is heparin-, heparinase III-, and chlorate-sensitive, suggesting that it involves, directly or indirectly, a heparan sulfate proteoglycan (HSPG). However, although efficient in terms of preventing ADAMTS-2 binding, heparinase III treatment did not significantly prevent the pro-apoptotic effect of ADAMTS-2 on endothelial cells. Although it could not be completely ruled out that it is related to an incomplete cleavage of HS-side chains, a more likely explanation would be that HSPG are not necessary to mediate the signaling induced by ADAMTS-2. There are indeed many examples showing that HSPG can bind growth factors (FGF-2, VEGF, …), potentiating their biological activity by increasing their local concentration and availability near their specific receptors, but are not strictly required for the transmission of the growth factor signal [38, 39] . Affinity chromatography using ADAMTS-2 as a bait and colocalization studies identified nucleolin as a potential membrane receptor for ADAMTS-2. Nucleolin was initially described as a nucleolar protein participating in the transcriptional control of ribosomal RNA genes, in ribosomes maturation and assembly, and in the b Cryostat sections of tumors were stained by an anti-CD31 antibody for visualizing blood vessels (in brown). Bar 100 lm nucleocytoplasmic transport of ribosomal components [40, 41] . It has also been shown that nucleolin can translocate to the plasma membrane in some specific cell types such as endothelial cells and many transformed cells [42] . When present at the cell surface, it has been shown that nucleolin can interact with Erb B receptors or serves as a receptor for L-selectin, midkine and, most interestingly, endostatin [43] , a potent anti-angiogenic fragment of collagen XVIII. The implication of nucleolin in the control of angiogenesis was strengthened by recent publications showing that an antibody targeting the acidic domain of nucleolin caused apoptosis of cultured endothelial cells and was anti-angiogenic in vitro and in vivo [44] . A direct interaction between this acidic domain and ADAMTS-2 would not be surprising considering that ADAMTS-2 has affinity for the negatively charged heparin and HSPG and that the heparin-binding domain of endostatin is required for its efficient binding on the acidic domain of nucleolin. Moreover, a specific antagonist of cell-surface nucleolin reduces the phosphorylation of Erk1/2 within a few minutes and suppresses tumor growth and angiogenesis [45] , two features also observed here for ADAMTS-2. The hypothesis that nucleolin is a receptor mediating the proapoptotic effect of ADAMTS-2 may seemed challenged by the observation that HEK 293-EBNA cells are not affected by ADAMTS-2 although they express nucleolin at Fig. 11 The catalytic activity of ADAMTS-2 is dispensable for antiangiogenic activity. a Sypro Ruby staining of purified control preparation (control), wild-type ADAMTS-2 (wtTS2) or catalytically inactive ADAMTS-2 (mTS-2). Asterisks indicate the most abundant form of ADAMTS-2 (* for wild-type ADAMTS-2 and ** for catalytically inactive ADAMTS-2). b HUVEC or HMEC were seeded on gelatin coats for 3 h in serum-free EBM and cultured for 16 h in medium supplemented with the control preparation (control), the wild-type ADAMTS-2 (wtTS-2) or catalytically inactive ADAMTS-2 (mTS-2), both at 5 lg/ml. Bar 100 lm. c The proliferation rate of HUVEC was measured by 3 H-thymidine uptake in cultures (n = 6) in the presence of wtTS2 (dark grey bar), of mTS2 (light grey bar) both at 5 lg/ml, or of the same amount of control preparation (0 lg/ml, black bar). The results are representative of three separate experiments (***p \ 0.001). d HMEC were incubated for 6 h at 8°C in serum-free medium supplemented with wild-type ADAMTS-2 (a) or catalytically inactive ADAMTS-2 (b) both at 2 lg/ml and immunostained for the presence of ADAMTS-2 immobilized at the cell surface. Bar 50 lm their surface (not shown). Similar data have been obtained with endostatin, which induces apoptosis in endothelial cells and some transformed cells while other cell types, although expressing nucleolin, are not altered [43] . Cellspecific intracellular pathways or the requirement of specific membrane co-receptors may explain this apparent discrepancy. Due to its vital importance for many cellular processes, we consider that repression of nucleolin by RNAi would not be appropriate for evaluating its implication as a ''receptor'' mediating apoptosis. Moreover, the amount of cell surface nucleolin may not be directly correlated to its overall abundance. Specific targeting of membrane nucleolin would be more suitable but is currently impossible because of the unavailability of blocking antibodies.
The antiangiogenic properties of ADAMTS-2 were also assessed in vivo. In a choroidal neovascularization model [46] , a reproducible and significant increase of neovascularization was observed in ADAMTS-2 -/-mice as compared to wild-type animals, supporting an antiangiogenic function for ADAMTS-2 in vivo. In a second model, HEK 293-EBNA cells were grafted subcutaneously to induce formation of tumors in nude mice [47] . The parental cells formed rapidly growing tumors characterized by the development of a dense network of functional blood vessels. When cells expressing wild-type ADAMTS-2 were used, tumor growth was drastically reduced, the small cell plugs were whiter and many necrotic areas were detected. Since control cells and cells expressing ADAMTS-2 grow at a similar rate, all these observations are most probably related to the absence of an efficient blood supply since only small and collapsed vessels are present in these tumors, again illustrating the anti-angiogenic properties of ADAMTS-2.
The same models were used to identify the specific domain(s) of ADAMTS-2 that is responsible for its antiangiogenic effects. Three different types of mutated ADAMTS-2 were produced. The catalytically inactive ADAMTS-2, resulting from a point mutation in the metalloproteinase domain, could be purified with the same efficiency as the wild-type enzyme. However, its molecular size is different since a functional catalytic pocket is required for the autocatalytic processing of PNP terminal domain [19] . As an additional difference, it was found that this incompletely processed form tends to form aggregates and to precipitate when purified and concentrated in physiological saline conditions (D. Hulmes, unpublished data). The two other recombinant enzymes, lacking either the central or the C-terminal domains, could not be sufficiently purified using procedures developed for the wildtype ADAMTS-2, most probably due to the absence of specific sequences and glycosylation required for affinity chromatography. Therefore only the recombinant ADAMTS-2 lacking metalloproteinase activity was evaluated in vitro for its effects on angiogenesis. It binds on endothelial cells and alters their morphology and proliferation rate, although to a lesser extent than the wild-type enzyme. It clearly demonstrates that the effect of ADAMTS-2 on endothelial cells does not directly involve its catalytic activity. It also shows that the persistence of the PNP domain has functional consequences in in vitro model of angiogenesis possibly by modifying availability and/or exposure of specific domains at the surface of the molecule or by reducing the solubility and therefore the specific concentration of ADAMTS-2. As the model of tumor growth does not require a purification process, it was used to evaluate the effect of the three mutant forms of ADAMTS-2 (Fig. 12) . The catalytically inactive ADAM-TS-2 efficiently prevented tumor growth, in agreement with the in vitro data. The two other mutated variants lacking specific domain were also active in restricting tumor growth. This would indicate that a common domain is responsible for the effect. The pro-domain is certainly not implicated since it is cleaved during secretion and is not present in purified enzyme used in vitro [19] . This would indicate that the short aminoterminal extremity of the metalloproteinase domain and/or the 132 amino acidlong spacer domain, which are common in all these constructs, are possibly involved. The spacer domain of ADAMTS-4 or ADAMTS-5 has been shown to modulate the proteolytic activity of the enzyme [48] but a structural function unrelated to the enzymatic activity has never been described so far. As an alternative hypothesis, antiangiogenic activity could be operated by two different TSR1 domains: the first, which is the only one present in the ADAMTS-2 lacking the C-terminal domain, and any of the three TSR1 that are still conserved in the ADAMTS-2 deprived of its central domain. The initial observations of the antiangiogenic potential of TSR1 domains were made during the study of thrombospondins 1 and 2 [8] . Various other TSR1 domains from different types of proteins, including ADAMTS-4, -16 and -18, have been previously tested [49] . Some of them significantly reduced (10-50%) endothelial cell proliferation but only at much higher concentration (500 nM-20 lM) as compared to the active concentration of ADAMTS-2 used here (2 lg/ml; around 16 nM). It has also been shown that the first (but not the second) TSR1 of ADAMTS-5 inhibited proliferation and increased apoptosis of endothelial cells at concentration ranging from 100 to 1,000 nM. Concerning ADAMTS-1 its antiangiogenic effect largely results from its specific interactions with VEGF165 [13] or depends on its catalytic activity [16] , two mechanisms that are not implicated for ADAMTS-2. These data show that these closely related enzymes can affect angiogenesis with different efficiency and through different pathways. They also illustrate the significance and the complexity of their functions and, therefore, demonstrate the need of an extensive characterization of both their active domain(s) and their specific receptor(s).
